NCT05163483View on ClinicalTrials.gov

Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

July 1, 2022

Primary Completion Date

December 1, 2023

Study Completion Date

December 1, 2025

Conditions
Esophageal Squamous Cell Cancer, Adenocarcinoma of Esophagogastric Junction, Gastric Adenocarcinoma
Interventions
DRUG

Tucidinostat (chidamide), PD-1 inhibitor (Toripalimab), Bevacizumab

"Tucidinostat (chidamide), 30mg, po., biw, q3w Toripalimab, 240mg, ivgtt., d1, q3w Bevacizumab, 7.5mg/kg, ivgtt., d1, q3w~approximately 2 years"

Trial Locations (1)

510060

RECRUITING

Cancer center of Sun Yat-sen University, Guangzhou

All Listed Sponsors
lead

Ruihua Xu

OTHER